The Ependymoma drugs in development market research report provides comprehensive information on the therapeutics under development for Ependymoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Ependymoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Ependymoma and features dormant and discontinued products.
GlobalData tracks 23 drugs in development for Ependymoma by 21 companies/universities/institutes. The top development phase for Ependymoma is phase ii with 13 drugs in that stage. The Ependymoma pipeline has 21 drugs in development by companies and two by universities/ institutes. Some of the companies in the Ependymoma pipeline products market are: Bristol-Myers Squibb, Nationwide Children’s Hospital and Millennium Pharmaceuticals.
The key targets in the Ependymoma pipeline products market include Programmed Cell Death Protein 1, Protein Cereblon, and Proto Oncogene Tyrosine Protein Kinase Receptor Ret.
The key mechanisms of action in the Ependymoma pipeline product include Programmed Cell Death Protein 1 Antagonist with two drugs in Phase II. The Ependymoma pipeline products include 12 routes of administration with the top ROA being Oral and six key molecule types in the Ependymoma pipeline products market including Small Molecule, and Oncolytic Virus.
Ependymoma overview
Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms usually develop slowly over many months. The treatment of an ependymoma depends on a number of things, including general health, the size and position of the tumor, and whether it has spread to other parts of the brain or spinal cord.
For a complete picture of Ependymoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
